Tegoprubart
- Generic Name
- Tegoprubart
- Drug Type
- Biotech
- Unique Ingredient Identifier
- EK87C62XNH
Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 3
- Registration Number
- NCT06305286
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Eledon Pharmaceuticals
- Target Recruit Count
- 132
- Registration Number
- NCT06126380
- Locations
- 🇪🇸
Hospital Universitari de Bellvitge, Barcelona, Spain
🇫🇷Groupe Hospitalier Pellegrin, Bordeaux, France
🇫🇷CHU Grenoble-Alpes - Hopital Nord Michallon, Grenoble, France
Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
- Conditions
- Kidney Transplant Rejection
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Eledon Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT05983770
- Locations
- 🇺🇸
Tulane Medical Center, New Orleans, Louisiana, United States
🇺🇸University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)
- First Posted Date
- 2021-11-18
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Eledon Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT05125068
- Locations
- 🇹🇭
Chulalongkorn University, Pathum Wan, Bangkok, Thailand
🇹🇭Prince of Songkla University, Dusit, Bangkok, Thailand
🇦🇺Monash Medical Centre, Clayton, Victoria, Australia
Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Eledon Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT05027906
- Locations
- 🇧🇷
Fundação Oswaldo Ramos - Hospital do Rim, São Paulo, Brazil
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
🇦🇺Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Anelixis Therapeutics, LLC
- Registration Number
- NCT04711226
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
Multiple Doses of AT-1501-A201 in Adults With ALS
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Anelixis Therapeutics, LLC
- Target Recruit Count
- 54
- Registration Number
- NCT04322149
- Locations
- 🇺🇸
Augusta University, Augusta, Georgia, United States
🇺🇸Texas Neurology, P.A., Dallas, Texas, United States
🇺🇸Barrows Neurological Institute, Phoenix, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.